Clinical Psychopharmacology · Paper A
Depot antipsychotic kinetics
Depot (long-acting injectable) antipsychotics behave differently from oral drugs in a way that has both a major benefit and a real safety catch. Unlike a tablet, stopping the injections doesn't immediately stop the drug entering the bloodstream: so a patient who develops a severe side effect from a depot cannot simply have it withdrawn like a pill. That slow, ongoing release is exactly why depot side effects can't be reversed quickly.
Depot antipsychotics create a drug reservoir at the injection site, releasing the drug slowly over time. For many depot formulations, absorption from this reservoir is slower than the drug's usual elimination, so absorption itself, not elimination, sets the drug's prolonged apparent half-lifeThe time it takes for the amount of a drug in the body to fall by half.Read more →, an effect called 'flip-flop' kinetics. This gives smoother blood concentrations and less frequent dosing, and makes non-adherence visible when a patient misses an appointment. However, adverse effects cannot be rapidly reversed, since drug continues entering the circulation after injections stop. Oral tolerability should be established before a first depot dose, where the formulation recommends it: a patient given a depot with no prior oral trial who then develops a severe reaction shows exactly why that step exists. An oral trial first is therefore a genuine safety step, not just a formality. Take a patient given a first depot injection of a drug they have never taken orally, e.g. he develops severe rigidity days later, and the team cannot simply stop a tablet to reverse it because drug is still leaching from the injection site. Clinically, this is why an oral tolerability trial before the first depot dose, and a slower dose-titration schedule than for oral drugs, are both standard practice.
A depot (long-acting injectable) antipsychotic solves the adherence problem that plagues daily oral dosing, but it introduces a safety trade-off that a candidate must understand at the level of pharmacokinetics, not just as a memorised fact: once injected, a severe adverse reaction cannot simply be reversed by stopping treatment the way a tablet can.
A DEPOT is a slow-release injectable formulation designed to release a drug gradually from a reservoir at the injection site, rather than delivering it all at once. HALF-LIFE (the time taken for a drug's concentration in the blood to fall by half) is normally set by how fast the body eliminates a drug. FLIP-FLOP KINETICS is the phenomenon where, for a slow-release formulation, absorption from the injection site is slower than elimination, so absorption itself (not elimination) sets the drug's apparent half-life.
A common trap is assuming a depot behaves like an oral drug that simply lasts longer. Suppose a patient develops a severe extrapyramidal reaction shortly after a depot injection: unlike a tablet, which can be withheld to stop further absorption almost immediately, the depot reservoir keeps releasing drug into the circulation for days to weeks regardless of whether further injections are given, so the reaction cannot be rapidly reversed.
Ordinarily a drug's reflects how quickly the liver and kidneys clear it. A depot changes which process is rate-limiting: because absorption from the muscle depot is slower than the body's normal elimination rate, the observed, apparent half-life of the drug becomes governed by that slow absorption instead. This is exactly what "flip-flop kinetics" describes, and it is why depot blood levels rise and fall gradually over weeks rather than peaking and troughing daily like an oral dose.
A depot formulation creates a drug reservoir at the injection site that releases medication slowly over time. Because absorption is the rate-limiting step, blood concentrations stay smoother than with oral dosing, which needs less frequent administration and makes non-adherence visible: a missed appointment is obvious, unlike a missed tablet at home. Reaching a stable, steady-state blood level, however, takes weeks to months for many depot formulations, compared with days for oral drugs. Because drug continues entering the circulation after injections stop, any adverse effect that emerges cannot be rapidly reversed.
Do not confuse a depot's slow with an oral drug simply having a long half-life of its own: the mechanism is different: one is absorption-limited (flip-flop), the other elimination-limited. Do not confuse the "test dose" given before some depot regimens with a full treatment dose; a test dose checks local tolerability of the injection itself, not systemic drug tolerability.
Before starting many depot formulations, oral tolerability with the same or a related antipsychotic should be established first, where the product recommends it, precisely because a severe reaction to a depot cannot be quickly undone. A patient given a depot with no prior oral trial who then develops a severe reaction illustrates exactly the risk this step exists to catch. This is an assessment step, not a diagnostic test for or a new diagnostic criterion: the underlying diagnosis and treatment indication are established separately using ICD-11 or DSM-5 clinical criteria, while the depot decision assesses pharmacokinetic suitability, adherence risk, prior response, current adverse effects, and whether oral tolerability has been shown. In practice the investigations are ordinary antipsychotic-safety checks ? weight, metabolic bloods, where relevant, when risk is present, and extrapyramidal side-effect assessment ? rather than a special depot-only biomarker.
Management of a depot-related adverse effect focuses on symptomatic treatment of the reaction itself, since the causative drug cannot be cleared quickly; medication such as procyclidine may be used for extrapyramidal side effects while the depot continues to be slowly absorbed. Maudsley Prescribing Guidelines recommend the oral-tolerability step before a first depot dose for formulations where it is advised, and recommend planning dosing intervals around each specific product's known time to . On stopping a depot altogether, plasma levels fall slowly over weeks, unlike the rapid seen after stopping an oral antipsychotic.
"Flip-flop kinetics" in a stem means absorption, not elimination, is setting the . A stem describing a depot started without any prior oral trial, followed by a severe reaction, is testing the rationale for a test dose or oral lead-in. on a depot takes weeks to months, not days.
Depot antipsychotics trade the daily peaks and troughs of oral dosing for smoother blood levels and better adherence, but because absorption from the injection-site reservoir, rather than elimination, sets the drug's prolonged apparent (flip-flop kinetics), any adverse reaction that emerges after a depot injection cannot be rapidly reversed, which is exactly why an oral trial is recommended before a first depot dose for many formulations.